Alkeon Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-390,551
| Closed | -$73.7M | – | 138 |
|
|
2021
Q3 | $73.7M | Sell |
390,551
-268,031
| -41% | -$50.6M | 0.12% | 88 |
|
|
2021
Q2 | $112M | Hold |
658,582
| – | – | 0.16% | 75 |
|
|
2021
Q1 | $93M | Buy |
658,582
+76,497
| +13% | +$10.8M | 0.14% | 80 |
|
|
2020
Q4 | $75.7M | Buy |
582,085
+141,109
| +32% | +$18.3M | 0.12% | 80 |
|
|
2020
Q3 | $64.2M | Sell |
440,976
-66,524
| -13% | -$9.69M | 0.12% | 81 |
|
|
2020
Q2 | $75.2M | Buy |
507,500
+62,500
| +14% | +$9.26M | 0.19% | 69 |
|
|
2020
Q1 | $48.4M | Buy |
445,000
+15,000
| +3% | +$1.63M | 0.21% | 65 |
|
|
2019
Q4 | $49.5M | Sell |
430,000
-307,500
| -42% | -$35.4M | 0.18% | 63 |
|
|
2019
Q3 | $59.3M | Buy |
737,500
+185,000
| +33% | +$14.9M | 0.21% | 60 |
|
|
2019
Q2 | $40.1M | Buy |
552,500
+150,000
| +37% | +$10.9M | 0.16% | 64 |
|
|
2019
Q1 | $37.6M | Buy |
402,500
+232,500
| +137% | +$21.7M | 0.19% | 68 |
|
|
2018
Q4 | $12.4M | Buy |
+170,000
| New | +$12.4M | 0.08% | 75 |
|
|
2018
Q2 | – | Sell |
-4,540
| Closed | -$541K | – | 95 |
|
|
2018
Q1 | $541K | Sell |
4,540
-460
| -9% | -$54.8K | ﹤0.01% | 88 |
|
|
2017
Q4 | $635K | Buy |
+5,000
| New | +$635K | ﹤0.01% | 62 |
|